At baseline, the investigator decided, based on his/her judgment and clinical experience, on 1 primary target clinical pattern (PTCP) that included flexed elbow, flexed wrist, or clenched fist. The PTCP was treated with a predefined fixed dose (flexed elbow, 200 U; flexed wrist, 150 U; clenched fist, 100 U). For the muscle groups other than the PTCP, investigators decided upon the dose and number of injection sites per muscle within predefined ranges (refer to Tables S1–S3 in the Supplementary Material, available online), based on their clinical judgment and the individual condition of the subject. Doses complied with the dose ranges approved for incobotulinumtoxinA in Europe.13 The total dose was fixed at 400 U of incobotulinumtoxinA (using a 2.0 ml per 100 U dilution with preservative‐free saline) or the corresponding volume of placebo (8.0 ml). The maximum injection volume per injection site was 1.0 ml, corresponding to 50 U of incobotulinumtoxinA. Injections were to be guided by electromyography and/or electrical nerve stimulation. Ultrasound guidance was allowed as a supplementary technique at the discretion of the investigator. All muscle groups with an AS score ≥2 and the corresponding clinical pattern had to be treated.